- Home
- MRCC vs CRVS Comparison
MRCC vs CRVS Comparison
Compare MRCC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | CRVS |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.2M | 634.0M |
| IPO Year | 2012 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MRCC | CRVS |
|---|---|---|
| Price | $6.71 | $8.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $8.00 | ★ $13.75 |
| AVG Volume (30 Days) | 99.3K | ★ 1.0M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 15.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $2.54 |
| 52 Week High | $8.85 | $9.60 |
Technical Indicators
Market Signals| Indicator | MRCC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 51.32 |
| Support Level | $6.65 | $8.31 |
| Resistance Level | $6.80 | $9.60 |
| Average True Range (ATR) | 0.14 | 0.54 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 81.30 | 26.75 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).